Let's delve deeper. Simplera CGM to Help MDT in Advanced Diabetes Management Simplera, Medtronic’s first disposable, all-in-one CGM, features a sleek design that is half the size of its ...

Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Meanwhile, Boston Scientific is still waiting for antitrust regulators to conclude their review of its proposal to buy Axonics, which was announced in January.

Medtronic may be an underrated beneficiary of declining interest rates. That's because as rates come down, it becomes less ...

There is even more good news for Medtronic. The company recently earned U.S. clearance for a continuous glucose monitoring (CGM) system called Simplera. It also announced a partnership with Abbott ...

Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Medtronic MDT recently announced two major developments within its diabetes care business. The company received FDA approval for its Simplera continuous glucose monitor (CGM), which marks a ...

Medtronic (NYSE: MDT ... From catheters to neurostimulators to continuous glucose monitoring devices, the company has a broad range of products in its portfolio, and it's routinely coming out ...

Medtronic hasn't been growing its sales at an impressive clip of late. However, one of the company's segments looks increasingly promising. Medtronic has other growth opportunities and is a solid ...